Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-04-16
DOI
10.3389/fphar.2019.00362
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect
- (2018) Philipp F. Secker et al. Cell Death & Disease
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells
- (2018) Kelly J. Peyton et al. BIOCHEMICAL PHARMACOLOGY
- Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
- (2018) Νarjes Nasiri-Ansari et al. Cardiovascular Diabetology
- Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
- (2018) Claudio R. Scafoglio et al. Science Translational Medicine
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
- (2017) Kosuke Kaji et al. INTERNATIONAL JOURNAL OF CANCER
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Angiogenesis in the atherosclerotic plaque
- (2017) Caroline Camaré et al. Redox Biology
- Medication-Induced Nephrotoxicity in Older Patients
- (2016) Sergio Fusco et al. CURRENT DRUG METABOLISM
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Transendothelial glucose transport is not restricted by extracellular hyperglycaemia
- (2016) Sarka Tumova et al. VASCULAR PHARMACOLOGY
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
- (2016) Linda A. Villani et al. Molecular Metabolism
- Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants
- (2015) Damayanthi Devineni et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
- (2014) Ivana Vrhovac et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- A Ligand-Independent VEGFR2 Signaling Pathway Limits Angiogenic Responses in Diabetes
- (2014) C. M. Warren et al. Science Signaling
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Physiological cyclic strain promotes endothelial cell survival via the induction of heme oxygenase-1
- (2013) Xiao-ming Liu et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Heme oxygenase-1 counteracts contrast media-induced endothelial cell dysfunction
- (2013) Chao-Fu Chang et al. BIOCHEMICAL PHARMACOLOGY
- All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database
- (2013) K. S. Taylor et al. DIABETES CARE
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
- (2013) Eiji Kurosaki et al. PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers
- (2012) Tobias Brand et al. ADVANCES IN THERAPY
- Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury
- (2011) Mette K. Hagensen et al. CARDIOVASCULAR RESEARCH
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- A Comparison of Methods for Quantifying Angiogenesis in the Matrigel Assay In Vitro
- (2011) Cheen Peen Khoo et al. TISSUE ENGINEERING PART C-METHODS
- Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
- (2009) Jian Xu et al. CIRCULATION
- Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial progenitor cells
- (2009) Jinglian Yan et al. JOURNAL OF VASCULAR SURGERY
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
- (2008) Zhang Weihua et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started